182 related articles for article (PubMed ID: 37097441)
1. Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects.
Kang P; Cho CK; Jang CG; Lee SY; Lee YJ; Choi CI; Bae JW
Arch Pharm Res; 2023 May; 46(5):438-447. PubMed ID: 37097441
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers.
Shao H; Ren XM; Liu NF; Chen GM; Li WL; Zhai ZH; Wang DW
J Clin Pharm Ther; 2010 Jun; 35(3):351-60. PubMed ID: 20831536
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.
Zhang Y; Si D; Chen X; Lin N; Guo Y; Zhou H; Zhong D
Br J Clin Pharmacol; 2007 Jul; 64(1):67-74. PubMed ID: 17298483
[TBL] [Abstract][Full Text] [Related]
4. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
Yin OQ; Tomlinson B; Chow MS
Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
[TBL] [Abstract][Full Text] [Related]
5. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects.
Tan B; Zhang YF; Chen XY; Zhao XH; Li GX; Zhong DF
Eur J Clin Pharmacol; 2010 Feb; 66(2):145-51. PubMed ID: 19847408
[TBL] [Abstract][Full Text] [Related]
6. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide.
Xu H; Williams KM; Liauw WS; Murray M; Day RO; McLachlan AJ
Br J Pharmacol; 2008 Apr; 153(7):1579-86. PubMed ID: 18204476
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
[TBL] [Abstract][Full Text] [Related]
9. Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects.
Kim NT; Cho CK; Kang P; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
Arch Pharm Res; 2022 Feb; 45(2):114-121. PubMed ID: 34952963
[TBL] [Abstract][Full Text] [Related]
10. Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics.
Choi CI; Bae JW; Lee YJ; Lee HI; Jang CG; Lee SY
J Clin Psychopharmacol; 2014 Feb; 34(1):139-42. PubMed ID: 24346747
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of effects of
Kanjanasilp J; Sawangjit R; Phanthaisong S; Borihanthanawuth W
Pharmacogenomics; 2021 Jul; 22(10):629-640. PubMed ID: 34060344
[No Abstract] [Full Text] [Related]
12. Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.
Song C; Li X; Mao P; Song W; Liu L; Zhang Y
Eur J Hosp Pharm; 2022 Jul; 29(4):198-201. PubMed ID: 32868386
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
14. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
[TBL] [Abstract][Full Text] [Related]
15. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.
Shon JH; Yoon YR; Kim MJ; Kim KA; Lim YC; Liu KH; Shin DH; Lee CH; Cha IJ; Shin JG
Br J Clin Pharmacol; 2005 May; 59(5):552-63. PubMed ID: 15842554
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.
Cheng Y; Wang G; Zhang W; Fan L; Chen Y; Zhou HH
Eur J Clin Pharmacol; 2013 Mar; 69(3):407-13. PubMed ID: 22842957
[TBL] [Abstract][Full Text] [Related]
17. Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem.
Byeon JY; Kim YH; Kim SH; Lee CM; Jung EH; Chae WK; Jang CG; Lee SY; Lee YJ
Arch Pharm Res; 2018 Aug; 41(8):861-866. PubMed ID: 30117082
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects.
Cho CK; Byeon JY; Kang P; Park HJ; Ko E; Mu CY; Jang CG; Lee SY; Lee YJ
Arch Pharm Res; 2023 Feb; 46(2):111-116. PubMed ID: 36564599
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite.
Kim SH; Kim DH; Byeon JY; Kim YH; Kim DH; Lim HJ; Lee CM; Whang SS; Choi CI; Bae JW; Lee YJ; Jang CG; Lee SY
Arch Pharm Res; 2017 Mar; 40(3):382-390. PubMed ID: 27864660
[TBL] [Abstract][Full Text] [Related]
20. CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide.
Yang F; Xiong X; Liu Y; Zhang H; Huang S; Xiong Y; Hu X; Xia C
Sci Rep; 2018 Jul; 8(1):10994. PubMed ID: 30030468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
